|Study Type:||Phase I|
|Stage:||Follow up complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA administered with needlefree jet injector versus needle/syringe and of MF5-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants
HVTN 111 is a Phase I clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using DNA-HIV-PT123 and bivalent subtype C gp120 with MF59 administered via biojector and needle/syringe.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.